Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia.

Pediatric blood & cancer - 1 Oct 2011

Lopez-Lopez Elixabet, Martin-Guerrero Idoia, Ballesteros Javier, Piñan M Angeles, Garcia-Miguel Purificacion, Navajas Aurora, Garcia-Orad Africa

Abstract excerpt

BACKGROUND: Methotrexate (MTX) is an important component of the therapy for childhood acute lymphoblastic leukemia. Treatment with high-dose MTX often causes toxicity, recommending a dose reduction and/or cessation of treatment. Polymorphisms in genes involved in the MTX metabolism have been associated with toxicity with controversial results. The discrepancies could be due to differences in treatment protocols...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic
Share to Child, Preschool

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Infant

Share to Liver-Specific Organic Anion Transporter 1

Share to Methotrexate

Share to Organic Anion Transporters

Share to Polymorphism, Restriction Fragment Length

Share to Precursor Cell Lymphoblastic Leukemia-Lymphoma

Source

Identifiers

PMID: 21387541
DOI: 10.1002/pbc.23074

Genes

ABCB1
ABCG2
MTHFR
RFC1
SHMT1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia.PMID 21387541Read ↗

Polymorphisms in the methotrexate transport pathway: a new tool for MTX plasma level prediction in pediatric acute lymphoblastic leukemia.Semantic proximity Read ↗

Methotrexate Disposition in Pediatric Patients with Acute Lymphoblastic Leukemia: What Have We Learnt From the Genetic Variants of Drug TransportersSemantic proximity Read ↗

MiR-pharmacogenetics of methotrexate in childhood B-cell acute lymphoblastic leukemia.Semantic proximity Read ↗

Pharmacogenetic aspects of efficacy and safety of methotrexate treatment in pediatric acute lymphoblastic leukemia.Semantic proximity Read ↗

The Role of Candidate Polymorphisms in Drug Transporter Genes on High-Dose Methotrexate in the Consolidation Phase of the AIEOP-BFM ALL 2009 Protocol.Semantic proximity Read ↗

Pharmacogenomic Markers of Methotrexate Response in the Consolidation Phase of Pediatric Acute Lymphoblastic Leukemia Treatment.Semantic proximity Read ↗

Genetic polymorphisms in candidate genes predict increased toxicity with methotrexate therapy in Lebanese children with acute lymphoblastic leukemia.Semantic proximity Read ↗

Polymorphisms in methotrexate transporters and their relationship to plasma methotrexate levels, toxicity of high-dose methotrexate, and outcome of pediatric acute lymphoblastic leukemia.Semantic proximity Read ↗

Effects of SLCO1B1 on elimination and toxicities of high-dose methotrexate in pediatric acute lymphoblastic leukemia.Semantic proximity Read ↗

Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia.Semantic proximity Read ↗

Influence of SLCO1B1 polymorphism on maintenance therapy for childhood leukemia.Semantic proximity Read ↗

MTHFR polymorphisms in childhood acute lymphoblastic leukemia: influence on methotrexate therapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.